Pulse Biosciences (NSDQ:PLSE) said yesterday that the FDA asked for more data on the 510(k) application for its CellFX dermatology device and reported higher-than-expected first-quarter losses, sending its share price down. Hayward, Calif.-based Pulse is seeking an indication for treating general benign lesions including sebaceous hyperplasia and seborrheic keratosis. The company said it received a letter […]
Pulse Biosciences
Pulse Biosciences closes $45m round
Pulse Biosciences (NSDQ:PLSE) said late last week it closed a $45 million rights offering. In the offering, the Hayward, Calif.-based company issued approximately 3.6 million shares of common stock at approximately $12.57 per share for total gross proceeds of $45 million. Pulse Bioscience board chair Robert Duggan, who owns 35% of the company’s outstanding common stock […]
Rights offering pulls in $45m for Pulse Biosciences
Pulse Biosciences (NSDQ:PLSE) said today that it raised $45 million in an over-subscribed rights offering. The price per share for the offering, which closed yesterday, was equivalent to the five-day volume-weighted average share price at $12.5658 apiece, Hayward, Calif.-based Pulse said. The company received subscriptions and over-subscriptions for 4,023,779 shares, topping the original offering of 3,581,148 […]
Pulse Biosciences launches $45m rights offering
Pulse Biosciences (NSDQ:PLSE) said yesterday that it launched a rights offering targeted to its existing shareholders, looking to bring in approximately $45 million. Funds from the rights offering are slated to support continued development of applications for the Hayward, Calif.-based company’s Nano-Pulse Stimulation technology. Pulse Bioscience’s Nano-Pulse Stimulation system is a non-thermal tech platform designed to […]
Pulse Biosciences registers for $45m rights offering
Pulse Biosciences (NSDQ:PLSE) yesterday filed for an upcoming rights offering targeted to its existing shareholders, looking to bring in approximately $45 million. Funds from the round will be used to support ongoing development of applications for the Hayward, Calif.-based company’s Nano-Pulse Stimulation technology. The Nano-Pulse Stimulation system is a novel, non-thermal tech platform designed to deliver nanosecond […]
Pulse Biosciences launches NPS cutaneous wart feasibility study
Pulse Biosciences (NSDQ:PLSE) said today that it launched a clinical feasibility study of its Nano-Pulse Stimulation platform intended to treat cutaneous warts. The Nano-Pulse Stimulation system is a novel, non-thermal tech platform designed to deliver nanosecond duration energy pulses intended to disrupt functions of internal cell structures while maintaining outer cell membranes, the Hayward, Calif.-based company said. […]
Pulse Biosciences’ nano-pulse stimulation tested in skin cancer patients
Pulse Biosciences, Inc. (Nasdaq:PLSE) has begun a clinical study to evaluate nano-pulse stimulation (NPS) platform in a common skin cancer, basal cell carcinoma (BCC). NPS is a non-thermal therapy that uses ultra-short, nanosecond-pulsed electric fields that directly affect and disrupt intracellular structures. It has been shown to induce immunogenic cell death in pre-clinical cancer models, according […]
Pulse Biosciences raises $30m in private placement
Pulse Biosciences (NSDQ:PLSE) said today that it agreed to sell 2 million of the company’s common stock at $15.02 apiece to investor Robert Duggan in a $30 million private placement. The company plans to use the net proceeds from the private placement for working capital or other general corporate purposes, according to a regulatory filing. Earlier […]
Pulse Biosciences pulls, plans to refile FDA 510(k) clearance bid for PulseTx nanostim
Pulse Biosciences (NSDQ:PLSE) said today it withdrew its FDA 510(k) application for its PulseTX nano-pulse stimulation platform, but said it has plans to resubmit the application “in the coming months.” The Burlingame, Calif.-based company’s PulseTx system uses short-duration electrical pulses directed at solid tumors to induce immunogenic cell death. The cell death process exposes the tumor […]
Pulse Biosciences seeks FDA 510(k) for PulseTx system
Pulse Biosciences (NSDQ:PLSE) said today that it submitted a 510(k) application to the FDA for its PulseTx nano-pulse stimulation system. The Burlingame, Calif.-based company’s PulseTx system uses short-duration electrical pulses directed at solid tumors to induce immunogenic cell death. The cell death process exposes the tumor cell antigens to the immune system, which triggers an […]
Ex-Pharmacyclics CEO, COO take 17% stake in Pulse Bioscience
Ex-Pharmacyclics CEO Robert Duggan and COO Maky Zanganeh have purchased a 17% stake in Pulse Biosciences. The 2 former execs purchased a total of 819,673 shares of common stock at $6.10 per share from the company and an additional, equal amount from existing shareholders, according to an SEC filing from the company. As part of […]